Ivan Hyep

CIK: 0002034668

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)17 (50.0%)

Position reduction

Option Exercises (M)16 (47.1%)

Derivative conversions

Awards (A)1 (2.9%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

BCAX

Bicara Therapeutics Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (34 total)

BCAX
Bicara Therapeutics Inc.
Aug 10, 2026
Sale(S)
Direct
12.5K shares at avg. $27.97$350K
BCAX
Bicara Therapeutics Inc.
Aug 10, 2026
Exercise(M)
Direct
12.5K shares at avg. $3.79$47K
BCAX
Bicara Therapeutics Inc.
Jul 8, 2026
Exercise(M)
Direct
12.5K shares at avg. $3.79$47K
BCAX
Bicara Therapeutics Inc.
Jul 8, 2026
Sale(S)
Direct
830 shares at avg. $30.31$25K
BCAX
Bicara Therapeutics Inc.
Jul 8, 2026
Sale(S)
Direct
4.4K shares at avg. $29.82$132K
BCAX
Bicara Therapeutics Inc.
Jul 8, 2026
Sale(S)
Direct
22.8K shares at avg. $28.60$651K
BCAX
Bicara Therapeutics Inc.
May 21, 2026
Sale(S)
Direct
9.2K shares at avg. $20.42$188K
BCAX
Bicara Therapeutics Inc.
May 21, 2026
Exercise(M)
Direct
9.2K shares at avg. $3.79$35K
BCAX
Bicara Therapeutics Inc.
Apr 21, 2026
Sale(S)
Direct
9.2K shares at avg. $23.00$212K
BCAX
Bicara Therapeutics Inc.
Apr 21, 2026
Exercise(M)
Direct
9.2K shares at avg. $3.79$35K
BCAX
Bicara Therapeutics Inc.
Mar 23, 2026
Sale(S)
Direct
9.2K shares at avg. $18.52$170K
BCAX
Bicara Therapeutics Inc.
Mar 23, 2026
Exercise(M)
Direct
9.2K shares at avg. $3.79$35K
BCAX
Bicara Therapeutics Inc.
Mar 4, 2026
Exercise(M)
Direct
3K shares at avg. $3.79$11K
BCAX
Bicara Therapeutics Inc.
Mar 4, 2026
Sale(S)
Direct
3K shares at avg. $18.25$54K
BCAX
Bicara Therapeutics Inc.
Mar 3, 2026
Exercise(M)
Direct
7.3K shares at avg. $3.79$28K
BCAX
Bicara Therapeutics Inc.
Mar 3, 2026
Exercise(M)
Direct
6.2K shares at avg. $3.79$24K
BCAX
Bicara Therapeutics Inc.
Mar 3, 2026
Sale(S)
Direct
13.6K shares at avg. $18.22$247K
BCAX
Bicara Therapeutics Inc.
Feb 2, 2026
Award(A)
Stock Option (Right to Buy)
Direct
125K shares-
BCAX
Bicara Therapeutics Inc.
Jan 22, 2026
Sale(S)
Direct
1.9K shares at avg. $18.15$34K
BCAX
Bicara Therapeutics Inc.
Jan 22, 2026
Exercise(M)
Direct
1.9K shares at avg. $3.79$7K
BCAX
Bicara Therapeutics Inc.
Dec 22, 2025
Sale(S)
Direct
9.2K shares at avg. $18.31$168K
BCAX
Bicara Therapeutics Inc.
Dec 22, 2025
Exercise(M)
Direct
9.2K shares at avg. $3.79$35K
BCAX
Bicara Therapeutics Inc.
Nov 24, 2025
Sale(S)
Direct
17.8K shares at avg. $18.55$330K
BCAX
Bicara Therapeutics Inc.
Nov 24, 2025
Exercise(M)
Direct
17.8K shares at avg. $3.79$67K
BCAX
Bicara Therapeutics Inc.
Nov 21, 2025
Exercise(M)
Direct
605 shares at avg. $3.79$2K

		Type	Shares	Price		Ownership
Aug 10, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	12,500	$27.97	$349,591	Direct
Aug 10, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	12,500	$3.79	$47,373	Direct
Jul 8, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	12,500	$3.79	$47,373	Direct
Jul 8, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	830	$30.31	$25,160	Direct
Jul 8, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	4,413	$29.82	$131,616	Direct
Jul 8, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	22,757	$28.60	$650,896	Direct
May 21, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	9,200	$20.42	$187,883	Direct
May 21, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	9,200	$3.79	$34,866	Direct
Apr 21, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	9,200	$23.00	$211,614	Direct
Apr 21, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	9,200	$3.79	$34,866	Direct
Mar 23, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	9,200	$18.52	$170,348	Direct
Mar 23, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	9,200	$3.79	$34,866	Direct
Mar 4, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	2,963	$3.79	$11,229	Direct
Mar 4, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	2,963	$18.25	$54,062	Direct
Mar 3, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	7,318	$3.79	$27,734	Direct
Mar 3, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	6,237	$3.79	$23,637	Direct
Mar 3, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	13,555	$18.22	$246,910	Direct
Feb 2, 2026	BCAX Bicara Therapeutics Inc.	Award(A) Stock Option (Right to Buy)	125,000	-	-	Direct
Jan 22, 2026	BCAX Bicara Therapeutics Inc.	Sale(S)	1,882	$18.15	$34,162	Direct
Jan 22, 2026	BCAX Bicara Therapeutics Inc.	Exercise(M)	1,882	$3.79	$7,132	Direct
Dec 22, 2025	BCAX Bicara Therapeutics Inc.	Sale(S)	9,200	$18.31	$168,492	Direct
Dec 22, 2025	BCAX Bicara Therapeutics Inc.	Exercise(M)	9,200	$3.79	$34,866	Direct
Nov 24, 2025	BCAX Bicara Therapeutics Inc.	Sale(S)	17,795	$18.55	$330,094	Direct
Nov 24, 2025	BCAX Bicara Therapeutics Inc.	Exercise(M)	17,795	$3.79	$67,439	Direct
Nov 21, 2025	BCAX Bicara Therapeutics Inc.	Exercise(M)	605	$3.79	$2,293	Direct

1-25 of 34 transactions

About Hyep Ivan

Hyep Ivan (SEC CIK 0002034668) files insider reports with the SEC as Chief Financial Officer of Bicara Therapeutics Inc. (BCAX).

Signal8 holds 13 ownership filings by Hyep Ivan (1 Form 3, 12 Form 4), filed between Sep 12, 2024 and Aug 12, 2026. Those filings report 34 transactions, from Oct 6, 2025 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hyep Ivan's filings is in BOSTON, MA.

Recent filings by Hyep Ivan

Aug 10, 2026: Open-market sale of BCAX shares (Form 4, code S).
Aug 10, 2026: Option exercise of BCAX shares (Form 4, code M).
Jul 8, 2026: Option exercise of BCAX shares (Form 4, code M).
Jul 8, 2026: Open-market sales of BCAX shares (3 lines, Form 4, code S).
May 21, 2026: Open-market sale of BCAX shares (Form 4, code S).

Other insiders filing for Bicara Therapeutics Inc. (BCAX)

Cohlhepp Ryan, President, COO & Interim CEO
Larson Jennifer, Chief Financial Officer
Mazumdar Claire, Chief Executive Officer
Bender Jeremy, Director
Oliger Christy J., Director
RA CAPITAL MANAGEMENT, L.P., Director

How to read Form 4 transaction codes